N/A
N=100
Pilocarpine Microneedles for Sweat Induction (PMN-SI)
Cystic Fibrosis
Bottom Line
View on ClinicalTrials.gov: NCT04732195 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
May 2023
Primary outcome: Primary: Amount of Sweat Collected — 41.2; 43.8 mg
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pilocarpine microneedle patch (Device); Pilocarpine Iontophoresis (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Emory University
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Amount of Sweat Collected |
41.2; 43.8 | — |
| SECONDARY Sweat Chloride Concentration |
31.2; 24.0 | — |
Summary
The investigators want to test in this non-randomized clinical trial a new method of administrating Pilocarpine medicine into the skin during the Sweat testing process that does not use any electrical current.
Eligibility Criteria
Inclusion Criteria
- Age >18 years
- Signed a written informed consent
- Not taking any medications
- No known medical diagnoses or chronic conditions
Exclusion Criteria
- Age <18 years
- Family history of Cystic Fibrosis
- History of skin disorders (eczema, psoriasis etc.) that could prevent sweat testing on forearms
- Current medication use
Data sourced from ClinicalTrials.gov (NCT04732195). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.